The drug has been allowed for restricted emergency use for treatment of suspected or laboratory-confirmed cases of COVID-19 in adults and children hospitalised with severe symptoms, subject to several safeguards, the source said

Gilead Sciences Inc have entered into non-exclusive licensing agreements with pharma firms including three domestic majors Cipla, Jubilant Life Sciences and Hetero for manufacture and distribution of remdesivir

According to the guidance issued on Wednesday, the ICMR stated these tests can be done on blood/serum/plasma samples, the results of which are available within 30 minutes and the test comes positive after 7-10 days of infection

While the legality of the issue will get sorted out in the coming days, one thing is certain that the scramble for a share in the thriving business of rapid diagnostic kit supplies for COVID-19 is leaving several grey areas for potential legal tussles

The vaccine is expected to provide long-lasting protection with a single dose administration with an anticipated safety profile similar to other licensed vaccines for active immunisation, said Indian Immunologicals Limited (IIL)

Mylab is the first Indian company to get commercial approval for its testing kits named as Mylab PathoDetect COVID-19 Qualitative PCR kit; the testing kit is approved by Indian FDA/CDSCO and ICMR evaluation

Coronavirus India latest updates: Prime Minister Narendra Modi said on Tuesday that the nationwide lockdown will be in effect from midnight to save every Indian. The 21-day lockdown period is to prevent the further spread of COVID-19

According to the report 'India: the emerging hub for biologics and biosimilars', the Indian pharmaceutical companies have launched 123 biosimilars and currently have 201 active biosimilars covering multiple indications in the development pipeline

Nano-formulations are not entirely new drugs but medicines that have better quality because of the technology-led delivery mechanisms that are used to make its administration in the body more effective

Failed policies cause domestic manufactures to import medical devices, while the government wants India to list among top five medical devices manufacturing hubs in the world under the 'Make in India' initiative